Drugs / Aluminum Hydroxide Suspension
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06267872 | Oct 2024 → Dec 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aluminum Hydroxide Suspension | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06267872 ↗ |
| Route | Intramuscular | “Alum to be administered IM as 500 mcg (aluminum content)” NCT06267872 ↗ |